{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:31:24Z","timestamp":1793043084070,"version":"4.5.0"},"reference-count":30,"publisher":"BMJ","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"accepted":{"date-parts":[[2023,3,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the effectiveness of oral spironolactone for acne vulgaris in adult women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Pragmatic, multicentre, phase 3, double blind, randomised controlled trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Primary and secondary healthcare, and advertising in the community and on social media in England and Wales.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Women (\u226518 years) with facial acne for at least six months, judged to warrant oral antibiotics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Participants were randomly assigned (1:1) to either 50 mg\/day spironolactone or matched placebo until week six, increasing to 100 mg\/day spironolactone or placebo until week 24. Participants could continue using topical treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Primary outcome was Acne-Specific Quality of Life (Acne-QoL) symptom subscale score at week 12 (range 0-30, where higher scores reflect improved QoL). Secondary outcomes were Acne-QoL at week 24, participant self-assessed improvement; investigator\u2019s global assessment (IGA) for treatment success; and adverse reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From 5 June 2019 to 31 August 2021, 1267 women were assessed for eligibility, 410 were randomly assigned to the intervention (n=201) or control group (n=209) and 342 were included in the primary analysis (n=176 in the intervention group and n=166 in the control group). Baseline mean age was 29.2 years (standard deviation 7.2), 28 (7%) of 389 were from ethnicities other than white, with 46% mild, 40% moderate, and 13% severe acne. Mean Acne-QoL symptom scores at baseline were 13.2 (standard deviation 4.9) and at week 12 were 19.2 (6.1) for spironolactone and 12.9 (4.5) and 17.8 (5.6) for placebo (difference favouring spironolactone 1.27 (95% confidence interval 0.07 to 2.46), adjusted for baseline variables). Scores at week 24 were 21.2 (5.9) for spironolactone and 17.4 (5.8) for placebo (difference 3.45 (95% confidence interval 2.16 to 4.75), adjusted). More participants in the spironolactone group reported acne improvement than in the placebo group: no significant difference was reported at week 12 (72%\n                      <jats:italic>v<\/jats:italic>\n                      68%, odds ratio 1.16 (95% confidence interval 0.70 to 1.91)) but significant difference was noted at week 24 (82%\n                      <jats:italic>v<\/jats:italic>\n                      63%, 2.72 (1.50 to 4.93)). Treatment success (IGA classified) at week 12 was 31 (19%) of 168 given spironolactone and nine (6%) of 160 given placebo (5.18 (2.18 to 12.28)). Adverse reactions were slightly more common in the spironolactone group with more headaches reported (20%\n                      <jats:italic>v<\/jats:italic>\n                      12%; p=0.02). No serious adverse reactions were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Spironolactone improved outcomes compared with placebo, with greater differences at week 24 than week 12. Spironolactone is a useful alternative to oral antibiotics for women with acne.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"ISRCTN12892056\" ext-link-type=\"isrctn\">ISRCTN12892056<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmj-2022-074349","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T20:30:21Z","timestamp":1684269021000},"page":"e074349","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":51,"title":["Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial"],"prefix":"10.1136","volume":"381","clinical-trial-number":[{"clinical-trial-number":"isrctn12892056","registry":"10.18810\/isrctn"},{"clinical-trial-number":"isrctn12892056","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7264-5260","authenticated-orcid":false,"given":"Miriam","family":"Santer","sequence":"first","affiliation":[{"name":"Primary Care Research Centre, Faculty of Medicine, University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4776-0616","authenticated-orcid":false,"given":"Megan","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Southampton Clinical Trials Unit, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0241-7240","authenticated-orcid":false,"given":"Susanne","family":"Renz","sequence":"additional","affiliation":[{"name":"Southampton Clinical Trials Unit, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2747-4279","authenticated-orcid":false,"given":"Zina","family":"Eminton","sequence":"additional","affiliation":[{"name":"Southampton Clinical Trials Unit, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5432-7437","authenticated-orcid":false,"given":"Beth","family":"Stuart","sequence":"additional","affiliation":[{"name":"Primary Care Research Centre, Faculty of Medicine, University of Southampton, Southampton, UK"},{"name":"Wolfson Institute of Population Health, Faculty of Medicine and Dentistry, Queen Mary University of London, Yvonne Carter Building, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8098-9220","authenticated-orcid":false,"given":"Tracey H","family":"Sach","sequence":"additional","affiliation":[{"name":"Health Economics Group, Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0093-9125","authenticated-orcid":false,"given":"Sarah","family":"Pyne","sequence":"additional","affiliation":[{"name":"Health Economics Group, Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7954-8823","authenticated-orcid":false,"given":"Matthew J","family":"Ridd","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8939-7312","authenticated-orcid":false,"given":"Nick","family":"Francis","sequence":"additional","affiliation":[{"name":"Primary Care Research Centre, School of Primary Care, Population Sciences and Medical Education, University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2291-831X","authenticated-orcid":false,"given":"Irene","family":"Soulsby","sequence":"additional","affiliation":[{"name":"Primary Care Research Centre, School of Primary Care, Population Sciences and Medical Education, University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8991-3380","authenticated-orcid":false,"given":"Karen","family":"Thomas","sequence":"additional","affiliation":[{"name":"Primary Care Research Centre, School of Primary Care, Population Sciences and Medical Education, University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3549-3215","authenticated-orcid":false,"given":"Natalia","family":"Permyakova","sequence":"additional","affiliation":[{"name":"Southampton Clinical Trials Unit, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK"},{"name":"National Institute for Health and Care Research, Research Design Service South Central, Faculty of Medicine, University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3664-1873","authenticated-orcid":false,"given":"Paul","family":"Little","sequence":"additional","affiliation":[{"name":"Primary Care Research Centre, Faculty of Medicine, University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9341-6133","authenticated-orcid":false,"given":"Ingrid","family":"Muller","sequence":"additional","affiliation":[{"name":"Primary Care Research Centre, Faculty of Medicine, University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5826-2594","authenticated-orcid":false,"given":"Jacqui","family":"Nuttall","sequence":"additional","affiliation":[{"name":"Southampton Clinical Trials Unit, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9579-8021","authenticated-orcid":false,"given":"Gareth","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Southampton Clinical Trials Unit, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7785-7465","authenticated-orcid":false,"given":"Kim S","family":"Thomas","sequence":"additional","affiliation":[{"name":"Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Applied Health Services Research Building, University Park, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0473-3319","authenticated-orcid":false,"given":"Alison M","family":"Layton","sequence":"additional","affiliation":[{"name":"Skin Research Centre, Hull York Medical School, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"2025110102171908000_381.may15_6.e074349.1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.446"},{"key":"2025110102171908000_381.may15_6.e074349.2","first-page":"97","article-title":"Prevalence and risk factors of acne scarring among patients consulting dermatologists in the USA","volume":"16","author":"Tan","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"2025110102171908000_381.may15_6.e074349.3","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19477"},{"key":"2025110102171908000_381.may15_6.e074349.4","first-page":"525","article-title":"Presentation and management of acne in primary care: a retrospective cohort study","volume":"53","author":"Purdy","year":"2003","journal-title":"Br J Gen Pract"},{"key":"2025110102171908000_381.may15_6.e074349.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1800"},{"key":"2025110102171908000_381.may15_6.e074349.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.12.037"},{"key":"2025110102171908000_381.may15_6.e074349.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.09.078"},{"key":"2025110102171908000_381.may15_6.e074349.8","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15843"},{"key":"2025110102171908000_381.may15_6.e074349.9","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp20X713873"},{"key":"2025110102171908000_381.may15_6.e074349.10","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15081"},{"key":"2025110102171908000_381.may15_6.e074349.11","doi-asserted-by":"publisher","DOI":"10.3399\/BJGP.2021.0332"},{"key":"2025110102171908000_381.may15_6.e074349.12","first-page":"18","article-title":"Status report from the Scientific panel on antibiotic use in dermatology of the American Acne and Rosacea Society: Part 1: Antibiotic prescribing patterns, sources of antibiotic exposure, antibiotic consumption and emergence of antibiotic resistance, impact of alterations in antibiotic prescribing, and clinical sequelae of antibiotic Use","volume":"9","author":"Del Rosso","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"key":"2025110102171908000_381.may15_6.e074349.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00527-7"},{"key":"2025110102171908000_381.may15_6.e074349.14","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.3168"},{"key":"2025110102171908000_381.may15_6.e074349.15","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0245-x"},{"key":"2025110102171908000_381.may15_6.e074349.16","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00511-5"},{"key":"2025110102171908000_381.may15_6.e074349.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-053876"},{"key":"2025110102171908000_381.may15_6.e074349.18","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020880005846"},{"key":"2025110102171908000_381.may15_6.e074349.19","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2001.00839.x"},{"key":"2025110102171908000_381.may15_6.e074349.20","doi-asserted-by":"publisher","DOI":"10.3310\/hta9010"},{"key":"2025110102171908000_381.may15_6.e074349.21","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research . Guidance for industry. Acne vulgaris: developing drugs for treatment: Draft guidance. 2005."},{"key":"2025110102171908000_381.may15_6.e074349.22","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2025110102171908000_381.may15_6.e074349.23","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200321150-00001"},{"key":"2025110102171908000_381.may15_6.e074349.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.02.006"},{"key":"2025110102171908000_381.may15_6.e074349.25","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dey256"},{"key":"2025110102171908000_381.may15_6.e074349.26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-008085"},{"key":"2025110102171908000_381.may15_6.e074349.27","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.2260"},{"key":"2025110102171908000_381.may15_6.e074349.28","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04432-w"},{"key":"2025110102171908000_381.may15_6.e074349.29","unstructured":"Barbieri Lab. Spironolactone versus doxycycline for acne: a Comparative Non-Inferiority Evaluation (SD-ACNE) research study. 7 September 2022. https:\/\/barbierilab.bwh.harvard.edu\/clinical-trial-opportunities\/."},{"key":"2025110102171908000_381.may15_6.e074349.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.10.023"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj-2022-074349","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj-2022-074349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:17:29Z","timestamp":1761988649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj-2022-074349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":30,"alternative-id":["10.1136\/bmj-2022-074349"],"URL":"https:\/\/doi.org\/10.1136\/bmj-2022-074349","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]}}}